Treatment of the metabolic syndrome by siRNA targeting apolipoprotein CIII

Recio-López, P; Valladolid-Acebes, I; Hadwiger, P; Hossbach, M; Krampert, M; Prata, C; Berggren, PO; Juntti-Berggren, L

Valladolid-Acebes, I; Juntti-Berggren, L (通讯作者),Karolinska Inst, Rolf Luft Res Ctr Diabet & Endocrinol, Karolinska Univ Hosp L1, SE-17176 Stockholm, Sweden.

BIOFACTORS, 2023; 49 (1): 153

Abstract

Apolipoprotein CIII (apoCIII) is increased in obesity-induced insulin resistance and type-2 diabetes. Emerging evidences support the advantages of sma......

Full Text Link